Revenue of ₹8,853.34 crore was up 5.6% from the previous year’s ₹8,832.12 crore. It was up 4% compared to the street estimates of ₹8,676 crore.
The company’s earnings before interest, tax, depreciation and amortisation (EBITDA) declined 5% to ₹1,702.73 crore from ₹1,791.92 crore in the previous year. It was down 3% from Street expectations of ₹1,731 crore.Its margins contracted to 19.2% from 21.4% in the year-ago period. It was lower than Street estimates of 19.9%.
Global business
Aurobindo Pharma’s US business declined 13% to ₹3,543 crore from ₹4,072 crore the previous year.
Its EU business increased 30.2% to ₹2,795 crore from ₹2,147 crore last year.Its growth markets increased 24.7% in the fourth quarter to ₹980 crore from 786 crore.
Earnings Call Takeways
Aurobindo Pharma, in a post-earnings conference call, said it sees its EBITDA margin improving to more than 21% in FY27.
It said $400 million is a reasonable base assumption for the US business compared to $387 million in the fourth quarter.
The company may see US formulations revenue at $2 billion in a couple of years. Meanwhile, in Europe, the company is looking at double digit growth in constant currency.
Aurobindo Pharma said it is looking at in-licensing opportunities, added that it is currently concentrating on the Lannett acquisition.
Stock performance
Shares of Aurobindo Pharma are trading 5.8% lower on Friday at ₹1,458. The stock is still up 22% so far in 2026.
Also Read: PSU stock falls most in nearly two years after Q4 results trigger 10% drop
